Hollencrest Capital Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Hollencrest Capital Management’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11	Closed	-$554	–	1147
2023 Q1	$554	Hold	11	–	–	﹤0.01%	1061
2022 Q4	$569	Buy	+11	New	+$567	﹤0.01%	1054

Other funds holding GNOM

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

PFG

Prosperity Financial Group San Ramon, California $271M AUM 30.27% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MWAM

Manhattan West Asset Management Los Angeles, California $511M AUM 18.81% 1-Year Est. Return

Hollencrest Capital Management's GNOM Position: Q2 2023 in Review

Hollencrest Capital Management sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q2 2023, closing a stake of 11 shares — an estimated $554 sold.

Hollencrest Capital Management first reported a position in GNOM in Q4 2022 and held it in 2 quarters. The position peaked at $569 in Q4 2022. 63 funds tracked by Wall St. Rank hold GNOM as of Q2 2023.

Hollencrest Capital Management reported no remaining Global X Genomics & Biotechnology ETF position as of Q2 2023 after selling out during the quarter.
Hollencrest Capital Management sold 11 Global X Genomics & Biotechnology ETF shares in Q2 2023, an estimated $554.
Hollencrest Capital Management first reported a position in Global X Genomics & Biotechnology ETF in Q4 2022 and held it in 2 quarters.
Hollencrest Capital Management's Global X Genomics & Biotechnology ETF position peaked at $569 in Q4 2022.
63 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2023.

Based on Hollencrest Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.